BETA vs CHANDAN: Stock Comparison
BETA DRUGS is the larger company by market capitalisation. BETA DRUGS shows a higher ROCE and a higher net margin, while CHANDAN shows a lower P/E, a higher ROE and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BETA leads 6; CHANDAN leads 4 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | BETA | CHANDAN |
|---|---|---|
| Live Price | ₹2,055.2 | — |
| Day Change | -1.9% | — |
| Volume | 14,462 | — |
| 52-Week High | ₹2,807.9 | — |
| 52-Week Low | ₹990.1 | — |
| Distance from 52W High | -26.81% | — |
Valuation
| Metric | BETA | CHANDAN |
|---|---|---|
| Market Cap | ₹2,289 Cr | ₹495 Cr |
| P/E Ratio | 50.46x | 22.4x |
| P/B Ratio | 8.55x | 3.55x |
| EPS | ₹15.49 | ₹2.74 |
| Book Value | ₹220.79 | ₹72.1 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | BETA | CHANDAN |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 124.9% | -39.81% |
| Qtr Profit Growth | 177.83% | -10.49% |
Profitability & Leverage
| Metric | BETA | CHANDAN |
|---|---|---|
| ROE | 14.27% | 16.2% |
| ROCE | 18.59% | 14.55% |
| Net Margin | 10.78% | 0% |
| Operating Margin | 18.28% | 15.97% |
| Debt to Equity | 0.87x | 0.3x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | BETA | CHANDAN |
|---|---|---|
| Promoter Holding | 59.1%▼ 5.53 pp | 49.61%▲ 0.06 pp |
| FII Holding | 1.02%▼ 0.14 pp | 0.01% |
| DII Holding | 6.23%▲ 4.08 pp | 5.09%▲ 0.06 pp |
| Public Holding | 33.65%▲ 1.59 pp | 45.29%▼ 0.13 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BETA DRUGS and CHANDAN.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.